| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 211.01 | 18.0% | 7.2% |
| Total Income | 211.01 | 18.0% | 7.2% |
| Expenditure | 207.99 | 2.7% | 17.2% |
| PBT | -23.07 | 67.5% | 76.5% |
| Net Profit | 15.90 | 124.5% | 114.9% |
| OPM | 1.43% | 20.97pp | 29.13pp |
| NPM | 7.53% | 43.79pp | 61.73pp |
| EPS | 0.20 | 124.1% | 114.4% |
PTC Therapeutics Reports Q3 2025 Results
04 May 2026 · 4 May, 8:09 am
Summary
This document contains PTC Therapeutics, Inc.'s report on Form 8-K, announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is included as an exhibit. The company hosted a conference call on November 4, 2025, to review the financial results and provide corporate updates.
Informational and educational content only. Not investment advice.